TY - JOUR
T1 - Mapping of the three-dimensional lymphatic microvasculature in bladder tumours using light-sheet microscopy
AU - Tanaka, Nobuyuki
AU - Kaczynska, Dagmara
AU - Kanatani, Shigeaki
AU - Sahlgren, Cecilia
AU - Mitura, Przemysław
AU - Stepulak, Andrzej
AU - Miyakawa, Ayako
AU - Wiklund, Peter
AU - Uhlén, Per
N1 - Funding Information:
The authors would like to thank Prof. Justyna Szumiło, Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland for kindly providing human tissue samples. This study was supported by the Swedish Research Council (grants 2009-3364, 2013-3189, and 2017-00815 to P.U.), the Swedish Cancer Society (grant CAN 2013/802 and CAN 2016/801 to P.U.), the Linnaeus Center in Developmental Biology for Regenerative Medicine (DBRM) (P.U.), a Knut and Alice Wallenberg Foundation Grant to the Center for Live Imaging of Cells at the Karolinska (CLICK) Institutet (P.U.), the Royal Swedish Academy of Sciences (P.U.), the David and Astrid Hagelén Foundation (N.T.), and the Karolinska Institutet Research Foundation (N.T.).
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background: Cancers are heterogeneous and contain various types of irregular structures that can go undetected when examining them with standard two-dimensional microscopes. Studies of intricate networks of vasculature systems, e.g., the tumour lymphatic microvessels, benefit largely from three-dimensional imaging data analysis. Methods: The new DIPCO (Diagnosing Immunolabeled Paraffin-Embedded Cleared Organs) imaging platform uses three-dimensional light-sheet microscopy and whole-mount immunolabelling of cleared samples to study proteins and micro-anatomies deep inside of tumours. Results: Here, we uncovered the whole three-dimensional lymphatic microvasculature of formalin-fixed paraffin-embedded (FFPE) tumours from a cohort of 30 patients with bladder cancer. Our results revealed more heterogeneous spatial deviations in more advanced bladder tumours. We also showed that three-dimensional imaging could determine tumour stage and identify vascular or lymphatic system invasion with higher accuracy than standard two-dimensional histological diagnostic methods. There was no association between sample storage times and outcomes, demonstrating that the DIPCO pipeline could be successfully applied on old FFPE samples. Conclusions: Studying tumour samples with three-dimensional imaging could help us understand the pathological nature of cancers and provide essential information that might improve the accuracy of cancer staging.
AB - Background: Cancers are heterogeneous and contain various types of irregular structures that can go undetected when examining them with standard two-dimensional microscopes. Studies of intricate networks of vasculature systems, e.g., the tumour lymphatic microvessels, benefit largely from three-dimensional imaging data analysis. Methods: The new DIPCO (Diagnosing Immunolabeled Paraffin-Embedded Cleared Organs) imaging platform uses three-dimensional light-sheet microscopy and whole-mount immunolabelling of cleared samples to study proteins and micro-anatomies deep inside of tumours. Results: Here, we uncovered the whole three-dimensional lymphatic microvasculature of formalin-fixed paraffin-embedded (FFPE) tumours from a cohort of 30 patients with bladder cancer. Our results revealed more heterogeneous spatial deviations in more advanced bladder tumours. We also showed that three-dimensional imaging could determine tumour stage and identify vascular or lymphatic system invasion with higher accuracy than standard two-dimensional histological diagnostic methods. There was no association between sample storage times and outcomes, demonstrating that the DIPCO pipeline could be successfully applied on old FFPE samples. Conclusions: Studying tumour samples with three-dimensional imaging could help us understand the pathological nature of cancers and provide essential information that might improve the accuracy of cancer staging.
UR - http://www.scopus.com/inward/record.url?scp=85042923440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042923440&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0016-y
DO - 10.1038/s41416-018-0016-y
M3 - Article
C2 - 29515257
AN - SCOPUS:85042923440
SN - 0007-0920
VL - 118
SP - 995
EP - 999
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -